What if we could detect almost all cancers in the earliest stages when less-invasive treatments mean lifesaving cures? The answer: Mortality rates — and health care costs — would plummet because most cancers could be cured or controlled using existing therapies.
The good news is this innovation exists today in the form of multi-cancer early detection (MCED) from one blood test. The bad news is we don’t have an Eisenhower administration determined to deliver a medical game-changer to as many Americans as possible.
Instead, we have a Biden administration — in the form of the Federal Trade Commission and Chair Lina Khan that Biden named to head it — standing in the way and creating an impenetrable barrier to access to millions of cancer patients.
